Ocuphire Pharma Inc. Stock
Ocuphire Pharma Inc. Stock
Ocuphire Pharma Inc. gained 2.190% today.
We see a rather positive sentiment for Ocuphire Pharma Inc. with 6 Buy predictions and 1 Sell predictions.
Based on the current price of 1.58 € the target price of 18 € shows a potential of 1042.13% for Ocuphire Pharma Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Ocuphire Pharma Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Innovation" there were negative voices in the community.
Pros and Cons of Ocuphire Pharma Inc. in the next few years
Pros
?
S********** s********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ocuphire Pharma Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Ocuphire Pharma Inc. | 2.190% | -16.987% | -6.386% | -72.299% | -44.401% | - | - |
Immunic Inc. | 3.260% | -7.177% | -14.349% | -27.205% | -18.601% | -89.070% | - |
NanoViricides Inc. | 7.190% | 73.786% | 54.310% | 62.727% | 89.418% | -30.728% | -56.063% |
Synthetic Biologics Inc. | -1.010% | -10.506% | -15.632% | -44.766% | -11.625% | -91.663% | -93.202% |
Comments
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for OCUP provided by MarketBeat